Which medication is known to positively impact fetal growth in hypertensive mothers?

Methyldopa is known to positively impact fetal growth in hypertensive mothers due to its effectiveness in managing hypertension while being one of the safer options during pregnancy. It acts as a centrally acting alpha-2 adrenergic agonist, leading to decreased vascular resistance and reduced blood pressure without compromising uteroplacental blood flow, which is crucial for fetal development.

This medication has a long history of use in pregnant women and is associated with favorable outcomes when treating elevated blood pressure, helping to prevent complications such as intrauterine growth restriction. Maintaining appropriate blood pressure levels in hypertensive mothers is essential for ensuring adequate blood flow and nutrients to the fetus, thereby supporting healthy fetal growth.

In contrast, some of the other medications listed have different implications during pregnancy. For instance, lisinopril is an ACE inhibitor that is contraindicated during pregnancy due to the risk of fetal harm, especially in the second and third trimesters. Hydrochlorothiazide, while used in some cases, may not have the same level of evidence supporting its safety and efficacy in promoting fetal growth. Atorvastatin, a statin used primarily for cholesterol management, is also not recommended during pregnancy as it poses risks to the fetus. Therefore, methyldopa